Pharmacogenetics and pharmaconomics

dc.contributor.author	Μαλλής, Παναγιώτης	el
dc.contributor.author	Καλαργύρου, Κατερίνα	el
dc.contributor.author	Γεροντάρα, Γεωργία	el
dc.contributor.author	Μουρτζίκου, Αθηνά	el
dc.contributor.author	Μάτσης, Κωνσταντίνος	el
dc.date.accessioned	2015-02-02T09:04:49Z
dc.date.available	2015-02-02T09:04:49Z
dc.date.issued	2015-02-02
dc.identifier.uri	http://hdl.handle.net/11400/5430
dc.rights	Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ηνωμένες Πολιτείες	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/us/	*
dc.source	http://e-jst.teiath.gr/	en
dc.subject	Drug metamolism
dc.subject	P450 enzymes
dc.subject	Μεταβολισμός φαρμάκων
dc.subject	Ένζυμα P450
dc.subject	Pharmacogenetic
dc.subject	Pharmacogenomic
dc.subject	Φαρμακογενετική
dc.subject	CYP2C9
dc.subject	Φαρμακογονιδίωμα
dc.title	Pharmacogenetics and pharmaconomics	en
heal.type	journalArticle
heal.classification	Medicine
heal.classification	Pharmacology
heal.classification	Ιατρική
heal.classification	Φαρμακολογία
heal.classificationURI	http://id.loc.gov/authorities/subjects/sh00006614
heal.classificationURI	http://skos.um.es/unescothes/C02967
heal.classificationURI	N/A-Ιατρική
heal.classificationURI	N/A-Φαρμακολογία
heal.contributorName	Ρέγκλη, Αρετή	el
heal.language	en
heal.access	free
heal.publicationDate	2011
heal.bibliographicCitation	Mallis, P., Kalargyrou, K., Gerontara, G., Mourtzikou, A., Matsis, K., et al. (2011). Pharmacogenetics and pharmaconomics. "e-Journal of Science & Technology". [Online] 6(3): 63-71. Available from: http://e-jst.teiath.gr/	en
heal.abstract	Pharmacogenetics and Pharmacogenomics constitute an especial young field of research in the domain of pharmacology. Both work on genetic variations which occur in individuals resulting reduced drug efficacy and more adverse drug reactions. Pharmacogenetics, emphasizes the diversity of patients and their genetic background, set their response to a given drug therapy, making understood the biological variability whereas pharmacogenomic considers the effects they cause in an individual (patient) different medications. The differences are studied on gene expression induction and repression of genes. The drug metabolism in human body is acted out by the P450 enzymes. In mammals, xenobiotic metabolizing CYPs provide crucial protection from the effects of exposure to a wide variety of chemicals, including environmental toxins and therapeutic drugs. In Phase I reactions (oxidation, reduction, and hydrolysis) and phase II conjugation reactions of drug metabolism in human body (acetylation, glucuronidation, sulfation, and methylation) are influenced by a number of genetic polymorphisms. Because many of the polymorphisms causing adverse effects are the result of single nucleotide changes, then a SNP profile of an individual could be used to guide therapy. If the genotype of an individual was known in advance then better clinical decisions could be made. Currently, more than 30 families of enzyme complexes responsible for drug metabolism have been described in humans and numerous variations exist in the encoding the many enzymes and proteins. The interdependence of the genetic makes up a large pharmaceutical research field today. More new analysis techniques beyond the understanding of the disease is possible and the Pharmaceutical treatment as targeted and individualized therapy. The ultimate goal of studies is to make more effective and affordable (financially) regimens with fewer side effects and greater patient response.	en
heal.publisher	Νερατζής, Ηλίας	el
heal.publisher	Σιανούδης, Ιωάννης	el
heal.journalName	e-Journal of Science & Technology	en
heal.journalName	e-Περιοδικό Επιστήμης & Τεχνολογίας	el
heal.journalType	peer-reviewed
heal.fullTextAvailability	true